Canopy Growth Corp’s size and scale is unmatched, GMP Securities says

With the largest dried cannabis inventory and an eye towards injecting value added pot products into its lineup, Canopy Growth Corp. (Canopy Growth Stock Quote, Chart, News: TSX:WEED) is poised to be the clear leader in Canada’s marijuana sector, says analyst Martin Landry with GMP Securities. In a research update to clients on Tuesday, the analyst reiterated his “Buy” rating and $40.00 target price.

Canada’s recreational marijuana industry is only a few months away (sometime in August is the federal government’s current timeline), and all of the sector’s major players are still building their greenhouses, warehouses and shipping facilities.

But after a recent visit to Canopy’s Smiths Falls HQ, Landry says that he expects the company to take the lead once the rec market begins.

“We came away from our visit of the Smiths Falls campus with more visibility on Canopy’s readiness to tackle the opening of the recreational market,” he says. “The expansion will provide the company with industrial scale production capacity for infused food and drinks, something key to tap the recreational market.”

Landry says that at 18 tonnes, Canopy has built up the largest inventory of dried cannabis, more than the next five largest public companies combined and representing 36 per cent of the total domestic inventory. He calls it a strong position from which to capture the biggest market share right out of the gate, and with its aim to produce value added products like infused drinks and infused food, the company will be able to derive higher profit margins than from selling dried cannabis alone.

“In our view, Canopy’s scale and reach is unmatched amongst Canadian licensed producers and we expect the company to generate significant sales growth in H2FY19,” says the analyst. “Despite a leading position, the company’s shares trade in line with peers on a 2019 EV/EBITDA basis, providing investors with an appealing entry point in our view.”

Landry projects Canopy’s revenue and EBITDA for 2018 at $78.1 million and negative $20.7 million, respectively, for 2019 at $376.9 million and $68.3 million, respectively and for 2020 at $1.030 billion and $273.0 million, respectively.

His $40.00 target price represents a potential return on investment of 18.1 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: weed
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

2 hours ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

4 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

5 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

6 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago